Ticker
ADMA

Price
2.68
Stock movement down
-0.03 (-1.11%)
Company name
ADMA Biologics Inc
Exchange
(NASDAQ
,
Currency
USD
)
Sector
Healthcare >
Biotechnology
Market cap
526.22M
Ent value
637.82M
Price/Sales
9.48
Price/Book
4.15
Div yield
-
Div growth
-
Growth years
-
FCF payout
-
Trailing P/E
-
Forward P/E
-
PEG
-
EPS growth
-
1 year return
92.81%
3 year return
-14.91%
5 year return
-2.17%
10 year return
-
Last updated: 2022-08-25

DIVIDENDS

ADMA does not pay dividends

VALUATION

Valuation Ratios

Loading...
Valuation Ratios data
Trailing P/E-
Price to OCF-
Price to FCF-
Price to EBITDA-
EV to EBITDA-

Valuation (Sales/Book Value)

Loading...
Valuation (Sales/Book Value) data
Price to Sales9.48
Price to Book4.15
EV to Sales11.50

FINANCIALS

Per share

Loading...
Per share data
Current share count196.35M
EPS (TTM)-0.43
FCF per share (TTM)-0.66

Income statement

Loading...
Income statement data
Revenue (TTM)55.49M
Gross profit (TTM)-31.95M
Operating income (TTM)-58.02M
Net income (TTM)-78.28M
EPS (TTM)-0.43
EPS (1y forward)-0.14

Margins

Loading...
Margins data
Gross margin (TTM)-57.59%
Operating margin (TTM)-104.58%
Profit margin (TTM)-141.07%

Balance Sheet

Loading...
Please create a free account or log in to access this chart
Balance Sheet data
Cash69.50M
Net receivables25.63M
Total current assets239.80M
Goodwill3.53M
Intangible assets1.55M
Property, plant and equipment53.22M
Total assets308.03M
Accounts payable14.12M
Short/Current long term debt146.36M
Total current liabilities31.57M
Total liabilities181.10M
Shareholder's equity126.93M
Net tangible assets126.93M

Cash flow

Loading...
Please create a free account or log in to access this chart
Cash flow data
Operating cash flow (TTM)-105.15M
Capital expenditures (TTM)13.78M
Free cash flow (TTM)-118.94M
Dividends paid (TTM)0.00

Financial returns

Loading...
Please create a free account or log in to access this chart
Financial returns data
Return on Equity-61.67%
Return on Assets-25.41%
Return on Invested Capital-19.39%
Cash Return on Invested Capital-29.46%

STOCK INFORMATION

Stock chart

Loading...
Stock price data
Open2.70
Daily high2.74
Daily low2.65
Daily Volume1.92M
All-time high12.49
1y analyst estimate5.13
Beta1.02
EPS (TTM)-0.43
Dividend per share-
Ex-div date-
Next earnings date8 Nov 2022

Downside potential

Loading...
Downside potential data
ADMAS&P500
Current price drop from All-time high-78.54%-12.18%
Highest price drop-91.27%-56.47%
Date of highest drop11 Oct 20219 Mar 2009
Avg drop from high-57.42%-11.38%
Avg time to new high91 days12 days
Max time to new high1948 days1805 days
COMPANY DETAILS
ADMA (ADMA Biologics Inc) company logo
Marketcap
526.22M
Marketcap category
Small-cap
Description
ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. It offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. The company also develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, it operates source plasma collection facilities. The company sells its products through independent distributors, sales agents, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.
Employees
527
Investor relations
-
SEC filings
CEO
Adam S. Grossman
Country
USA
City
Ramsey
Stock type
Common stock
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
All newsPress releases
A new White House program will likely boost the entire biotech industry. And it makes these seven names some outstanding biotech stocks to buy for the fourth quarter. The new National Biotechnology an...
September 15, 2022
Penny stocks are those which typically trade at $5 per share or less. Most penny stocks represent small companies that likely trade via over-the-counter (OTC) transactions, although some do trade on ...
August 31, 2022
ADMA Biologics (NASDAQ: ADMA), typically one of the more under-the-radar coronavirus stocks, was very much on the radar of many investors on Thursday. ADMA attracted a degree of renown in 2020 after ...
August 11, 2022
Adma Biologics (ADMA) delivered earnings and revenue surprises of 22.22% and 8.77%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
August 10, 2022
2Q2022 Total Revenues Were $33.9 Million, a 90% Y-o-Y Increase Grew 2Q2022 Gross Profit to $7.8 Million, Up 112% Over 1Q2022 Narrowed 2Q2022 Net Losses to $13.8 Million, a 45% Improvement Over 1Q2022 ...
August 10, 2022
Usually, when one insider buys stock, it might not be a monumental event. But when multiple insiders are buying like...
August 10, 2022
Vascular Biogenics (VBLT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
August 8, 2022
Adma Biologics (ADMA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
August 3, 2022
Conference Call Scheduled for August 10, 2022, at 4:30 p.m. ETRAMSEY, N.J. and BOCA RATON, Fla., Aug. 03, 2022 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), an end...
August 3, 2022
While not a mind-blowing move, it is good to see that the ADMA Biologics, Inc. ( NASDAQ:ADMA ) share price has gained...
June 26, 2022
Next page